Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standardization of Latex allergenic extract in HEP units
2005-001880-68Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Jul 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of latex allergen extract in latex allergy, sponsored by LETI Pharma. Primary endpoint: Immediate phase skin reaction wheal area. Started Jul 2005; status: completed.
02
Drugs
latex allergen extract
03
Conditions
latex allergy
Beyond the preview
Go deeper on 2005-001880-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001880-68.